Vir Biotechnology Shares Drop 13% After $150 Million Offering

Vir Biotechnology shares fell 13% to $10.50 in premarket trading Friday after the company priced a public stock offering expected to raise about $150 million before expenses. The decline followed a strong run for the stock, which had roughly doubled in value year to date through Thursday’s close.

November 13, 2026, 02:53 PM 759 0

Vir Biotechnology Shares Drop 13% After $150 Million Offering

The biopharmaceutical company said late Thursday it will sell 15 million common shares to the public for $10 apiece. The proceeds are stated before underwriting costs, commissions and other offering expenses.

Vir also gave underwriters a 30-day option to buy up to 2.25 million additional shares at the public offering price, less underwriting discounts and commissions. Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers. The offering is expected to close Monday.

When reusing this material a link to Money Talk is required.